Generic Name and Formulations:
Buprenorphine 74.2mg (equivalent to 80mg of buprenorphine HCl); per implant; for subdermal use.
Indications for PROBUPHINE:
Maintenance treatment of opioid dependence in patients who have achieved and sustained prolonged clinical stability on low-to-moderate doses of transmucosal buprenorphine-containing product (eg, ≤8mg/day Subutex, Suboxone, or generic equivalent), as part of a complete treatment plan to include counseling and psychosocial support.
See full labeling. For opioid-tolerant patients only. Insert 4 implants subdermally in the upper arm for 6 months, then remove. Examine insertion site 1 week after procedure for infection or impaired wound healing. After first 6-month cycle, implants may be replaced by new implants at time of removal in the contralateral arm, if continuing treatment; maintain on previous dose of transmucosal buprenorphine if not inserted on same day as removal.
<16yrs: not established.
Risk of serious complications from insertion/removal of implants; see full labeling. Abuse potential (monitor). Risk of significant respiratory depression. Compromised respiratory function (eg, COPD, cor pulmonale, decreased respiratory reserve, hypoxia, hypercapnia, pre-existing respiratory depression). Accidental exposure may cause fatal overdose (esp. in children). Adrenal insufficiency. Obtain LFTs at baseline then monitor periodically; evaluate if hepatic event is suspected. Moderate or severe hepatic impairment; avoid. Head injury. Intracranial lesions. Biliary tract dysfunction. Acute abdomen. Myxedema. Hypothyroidism. CNS depression. Coma. Toxic psychoses. Prostatic hypertrophy. Urethral stricture. Acute alcoholism. Delirium tremens. Kyphoscoliosis. History of keloid formation, connective tissue disease (eg, scleroderma), or recurrent MRSA infections. Avoid abrupt cessation. Opioid-naïve. Elderly. Debilitated. Pregnancy; potential neonatal opioid withdrawal syndrome during prolonged use. Labor & delivery. Nursing mothers: monitor infants.
Potentiated by CYP3A4 inhibitors (eg, azole antifungals, macrolides, HIV protease inhibitors): monitor and may need dose adjustments or discontinuation. Antagonized by CYP3A4 inducers: monitor for opioid withdrawal and consider dose adjustments or discontinuation. Concomitant NNRTIs (eg, efavirenz, nevirapine, etravirine, delavirdine) or PIs (eg, atazanavir with/without ritonavir): monitor. Risk of respiratory or CNS depression with concomitant opioid analgesics, general anesthetics, benzodiazepines, phenothiazines, other tranquilizers, sedative/hypnotics, alcohol, or other CNS depressants; caution and consider dose reduction of one or both drugs. Risk of serotonin syndrome with concomitant SSRIs, SNRIs, TCAs, 5-HT3 receptor antagonists, mirtazapine, trazodone, tramadol, MAO inhibitors; monitor and discontinue if suspected.
Opioid (partial agonist-antagonist).
Implant-site pain/pruritus/erythema, headache, depression, constipation, nausea, vomiting, back pain, toothache, oropharyngeal pain; signs/symptoms of opioid withdrawal, insertion/removal complications (eg, neural/vascular injury, protrusion, expulsion, infection), orthostatic hypotension, hepatitis, hypersensitivity reactions.
Kit—1 (4 implants w. applicator)
Psychiatry Advisor Articles
- Continuing Research, Emerging Treatments Hold Promise for Treating Anorexia Nervosa
- ACOG Update: Marijuana Use Discouraged During Pregnancy, Breastfeeding
- Asenapine Prevents Recurrence of Mood Events in Bipolar Disorder
- Venlafaxine XR Safe, Effective in Treating Generalized Anxiety Disorder
- Duration of Untreated Depression Predicts Depression Severity
- CBT, Acceptance Commitment Therapy Helpful for Those With Chronic Pain
- Suicidal Behavior, Thoughts Associated With Perfectionist Tendencies
- Depression Reduced by Social Belonging, Feelings of Inclusion
- Sleep Disturbance May Be Causal Factor in Psychotic Experiences
- Is Antidepressant Use in Pregnancy Tied to Psychiatric Disorders in Offspring?
- Elevated Dopamine Synthesis Capacity Observed in Both Bipolar and Schizophrenia
- SSRI Use Associated With Increased Type 2 Diabetes Risk in Young Adults
- Specialty Physicians Experiencing Lack of Income Growth
- Improved Patient-Provider Communication Needed Following Urgent Care Visits
- Cardiovascular Risk Management May Slow Neurocognitive Decline in HIV